Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aldeyra Therapeutics
Biotech
Aldeyra dry eye disease decision hit by FDA delay
The delay comes after the regulator sent a draft label for the drug candidate to the company in early December and Aldeyra responded with comments.
Darren Incorvaia
Dec 16, 2025 11:55am
Aldeyra drops and swaps RASP assets in response to data
Oct 28, 2025 9:10am
Aldeyra posts hit, miss for dry eye drug, plans FDA filing
May 6, 2025 7:05am
Aldeyra’s dry eye drug suffers second FDA rejection
Apr 3, 2025 8:46am
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Milestone resubmits NDA, Aldeyra readies 2nd chance filing
Mar 28, 2024 10:40am
